RNA-based therapeutics have expanded rapidly, with ASO-based interventions targeting SOD1 in ALS (tofersen), tau in AD, and huntingtin in HD advancing to clinical testing (39, 40, 77). This evidence concerns the gene HTT and amyotrophic lateral sclerosis.